Life Settlements and Heart Disease

Why Heart Disease Changes the Life Settlement Equation

Life settlement pricing is fundamentally an exercise in discounted cash flow. A licensed provider projects how many years of premiums it will pay before collecting the death benefit, then discounts that stream back to a present value. The single biggest input is the insured’s life expectancy, established through independent medical underwriting. A healthy 70-year-old might carry a 15-to-18-year life expectancy estimate; the same 70-year-old with class III congestive heart failure might be assigned 5 to 8 years. That difference can move an offer from a few percent of face value to 25% or more.

Cardiac disease is one of the most common impairments seen in settlement underwriting because it is prevalent in the 65+ population and because its progression is well documented in actuarial literature. Underwriters do not treat “heart disease” as a single category. They distinguish between stable, well-managed conditions — controlled hypertension, a stented artery with normal ejection fraction — and progressive or decompensated disease such as advancing heart failure, severe aortic stenosis awaiting intervention, or ischemic cardiomyopathy with a low ejection fraction.

For policyholders, the practical takeaway is counterintuitive: the health event that made new coverage unaffordable or unavailable is the same event that makes an existing policy more valuable on the secondary market. Understanding how health affects life settlement value generally will help you see where your specific cardiac profile fits.

Cardiac Conditions Underwriters Evaluate

Life expectancy underwriters review the full cardiac picture, not just the diagnosis on a claim form. Conditions that commonly appear in settlement files include:

• Coronary artery disease (CAD): number of vessels involved, history of stents or bypass grafting (CABG), and whether symptoms persist after revascularization.
• Congestive heart failure (CHF): New York Heart Association functional class, ejection fraction, hospitalization frequency, and whether the failure is ischemic or non-ischemic in origin.
• Prior myocardial infarction: how recent, extent of muscle damage, and post-event function.
• Valvular disease: aortic stenosis or mitral regurgitation severity, and whether repair or replacement (surgical or TAVR) has occurred.
• Arrhythmias: atrial fibrillation, pacemaker or ICD implantation, and stroke history connected to the rhythm disorder.
• Peripheral and cerebrovascular disease: often evaluated alongside cardiac disease because they share risk factors and compound mortality.

Comorbidities matter enormously. Heart disease combined with diabetes complications, chronic kidney disease, or COPD produces a materially shorter life expectancy estimate than any single condition alone, because these diseases accelerate one another. Underwriters also weigh functional status — can the insured climb stairs, walk unassisted, manage daily activities — since functional decline is a strong independent mortality predictor.

How Life Expectancy Reports Are Prepared

When a policyholder with cardiac disease pursues a settlement, the process typically includes obtaining two independent life expectancy (LE) reports from specialized medical underwriting firms. These firms — separate from the buyers — review attending physician statements, hospitalization records, echocardiogram and catheterization results, medication lists, and lab work, then apply mortality tables adjusted for the specific impairments found. Preparing the reports usually takes two to six weeks and is one reason the full settlement process runs 60 to 120 days.

For cardiac cases, a few records carry outsized weight. The most recent echocardiogram establishes ejection fraction, the workhorse measure of pumping function. Stress test and catheterization reports show the extent of blockage and ischemia. BNP or NT-proBNP lab values and hospitalization notes track heart failure severity over time. A cardiologist’s most recent consultation note often anchors the entire file because it summarizes trajectory: stable, improving, or declining.

Policyholders can help their own case by ensuring records are complete and current. An LE underwriter who cannot find a recent echo may default to more conservative (longer) assumptions, which lowers offers. The detailed mechanics of how these estimates translate into dollars are covered in our guide to life expectancy and settlement pricing. Regulation of the process is state-based, following the framework of the NAIC Life Settlements Model Act, which requires providers and brokers to be licensed.

What a Cardiac Diagnosis Can Mean for Offer Value

No two policies price identically, but general patterns hold. Per the GAO report on life settlements, settlements have typically paid roughly 10–35% of face value and about four to eight times cash surrender value. Where a cardiac case falls in that range depends on the severity tier the LE underwriters assign.

Mild, well-controlled disease — treated hypertension, a single stent years ago with full recovery — usually shaves only a year or two off standard life expectancy. Such cases may still qualify, particularly for insureds in their late 70s or 80s, but offers cluster at the lower end. Moderate disease — multi-vessel CAD, compensated CHF, atrial fibrillation with prior stroke — often produces LE estimates in the 7-to-12-year range and mid-range offers. Severe, progressive disease — NYHA class III/IV heart failure, ejection fraction below 30%, recurrent hospitalizations, inoperable valve disease — can push life expectancy under five years and drive offers toward the top of the range or beyond typical percentages.

If a physician has certified a life expectancy under 24 months, the transaction may instead qualify as a viatical settlement, which carries higher payout percentages and potentially tax-free treatment under IRC 101(g). Other value drivers matter too: premium cost relative to face value, policy type (universal life is most commonly settled), and carrier financial strength all move the number.

Cardiac Profile	Typical LE Underwriting View	General Effect on Settlement Value
Controlled hypertension or hyperlipidemia only	Minimal impairment; near-standard life expectancy	Low impact; qualification depends mostly on age and policy economics
Single stent, normal ejection fraction, no symptoms	Mild impairment; modest LE reduction	Modest lift; lower end of the 10–35% of face range
Multi-vessel CAD or CABG with residual symptoms	Moderate impairment; LE often 8–12 years	Meaningful lift; mid-range offers more likely
CHF (NYHA II–III), reduced ejection fraction	Significant impairment; LE often 5–9 years	Strong lift; upper-middle of typical range
Advanced CHF (NYHA III–IV), EF under 30%, recurrent hospitalizations	Severe impairment; LE may fall under 5 years	Top of range; may approach viatical territory
Physician-certified terminal prognosis (LE under 24 months)	Terminal classification	May qualify as a viatical settlement — higher payout and often tax-free under IRC 101(g)

Check Your Policy’s Living Benefits Before You Sell

Before pursuing a settlement, every cardiac patient should read their policy — or ask their carrier — for built-in living benefits. Many modern policies include an accelerated death benefit rider that pays a portion of the death benefit directly from the insurer upon terminal or chronic illness, often at no cost until exercised. Some policies add critical illness riders that trigger on a heart attack or specific cardiac events, or chronic illness riders that trigger when the insured cannot perform two of six activities of daily living.

These riders matter because they let you access value while keeping some or all of the remaining death benefit for your beneficiaries, and terminal-illness acceleration is frequently income-tax-free under IRC 101(g) — the IRS treats qualifying accelerated benefits like death proceeds. A settlement, by contrast, permanently transfers the entire policy to an investor.

That said, riders have real limits. Acceleration caps (often 25–75% of face value), waiting periods, condition definitions that a given cardiac diagnosis may not meet, and reductions to the remaining benefit can make a rider less useful than it first appears. Comparing the two paths side by side — covered in depth in life settlement vs. accelerated death benefit — is the right first step. A settlement often wins when premiums have become unaffordable, when the rider’s trigger definitions are not met, or when the policyholder needs more cash than the rider can advance.

A Realistic Walk-Through: One Cardiac Case

Consider a hypothetical 74-year-old with a $500,000 universal life policy, $28,000 in cash surrender value, and annual premiums of $19,000 that have become burdensome. Three years ago he underwent triple-vessel bypass surgery; this year his cardiologist documented an ejection fraction of 32% and NYHA class II–III heart failure symptoms. New coverage is out of reach, and the premium schedule is projected to escalate.

In a settlement process, his broker or advisor gathers five years of medical records and orders two LE reports. Suppose the reports come back at 78 and 84 months. Licensed providers model premium payments over that horizon, apply their required return, and bid. In a competitive auction, offers might plausibly land between $95,000 and $150,000 — roughly 19–30% of face value and four to five times his surrender value. He compares that against surrendering for $28,000, lapsing for nothing, accelerating under a rider his policy does not include, or keeping the policy by borrowing against cash value.

The numbers above are illustrative, not a promise — actual offers depend on the specific LE reports, premium structure, and buyer appetite at the time. But the shape of the decision is typical: a cardiac diagnosis converted a policy he was about to lapse into a six-figure asset. Whether selling is wise depends on his beneficiaries’ needs, his other resources, and the alternatives explored throughout life settlements with a serious health condition.

Downsides and Cautions Specific to Cardiac Sellers

An honest evaluation includes the drawbacks. First, the death benefit is gone. If a cardiac patient’s spouse or dependents rely on that payout, selling trades their future security for present cash — a trade that deserves family discussion. Second, taxes apply to most life settlements. Under IRS Rev. Rul. 2009-13 as modified by the 2017 tax act, proceeds up to your basis are tax-free, amounts from basis up to cash surrender value are ordinary income, and gains above that are capital gain. Only viatical-qualifying sellers (terminal illness, LE under 24 months) generally receive fully tax-free treatment — see the viatical settlement tax exclusion for details.

Third, a lump sum can affect means-tested benefits. Cash received may disqualify a recipient from Medicaid long-term care assistance until it is spent down under Medicaid rules, and can affect SSI. Fourth, cardiac prognosis is uncertain in both directions. Modern interventions — TAVR, advanced heart failure therapies, ICDs — sometimes extend life well beyond LE estimates, which is fine for the seller but underscores that estimates are probabilities, not predictions; conversely, selling and then living many more years without a policy may leave a coverage gap that cannot be refilled.

Finally, work only with licensed brokers and providers. In New Jersey, the Viatical Settlements Act under N.J.S.A. Title 17B requires licensing, enforced by the NJ Department of Banking and Insurance, and most states follow similar NAIC-based rules. Rescission windows of 15–30 days exist in most states if you change your mind after closing.

Steps to Take if You Have Heart Disease and an Unneeded Policy

A structured approach protects you from leaving money on the table or selling when you should not:

• 1. Inventory the policy. Confirm face value, policy type, premium schedule, cash surrender value, loans outstanding, and — critically — any accelerated death benefit, chronic illness, or long-term care riders already attached.
• 2. Clarify the goal. Premium relief, long-term care funding, debt payoff, or simply exiting an unneeded policy each point toward different solutions, including retained-death-benefit settlements that keep part of the coverage.
• 3. Gather cardiac records. Recent echocardiogram, cardiology notes, hospitalization summaries, and medication lists speed underwriting and support accurate — often shorter — LE estimates.
• 4. Confirm baseline eligibility. Most buyers look for age 65+ (younger with significant impairments), face value of roughly $100,000 or more, and a policy in force at least two years; see who qualifies for a life settlement.
• 5. Create competition. Multiple provider bids consistently produce better outcomes than accepting a single direct offer.
• 6. Model the after-tax, after-benefit picture. Involve a tax professional and, if Medicaid may ever be needed, an elder law attorney before signing.

Pine Lake’s role in this process is educational — mapping every option, including keeping the policy — so the decision is made with complete information rather than sales pressure.

---

Frequently Asked Questions

Can I sell my life insurance policy if I have congestive heart failure?

Yes, in many cases. Congestive heart failure is one of the impairments most commonly seen in life settlement underwriting, and it typically increases offer value because it shortens estimated life expectancy. Buyers will want recent records — ejection fraction, NYHA functional class, and hospitalization history — to price the policy. You generally still need to meet baseline criteria: a policy of roughly $100,000+ in face value, in force at least two years, and usually a permanent policy or convertible term. Severity matters; advanced CHF often produces materially higher offers than early-stage, well-compensated disease.

How much more is a life settlement worth after a heart attack?

There is no fixed premium for a heart attack; the effect depends on how much the event and its aftermath shorten your underwritten life expectancy. A remote, fully recovered MI with normal heart function may change little. A recent infarction with significant muscle damage, reduced ejection fraction, or subsequent heart failure can shorten LE estimates by years and move an offer meaningfully within the typical 10–35%-of-face-value range documented by the GAO. Two independent life expectancy reports, based on your actual cardiology records, determine where you land.

Does having a pacemaker or defibrillator affect life settlement eligibility?

A pacemaker or implantable cardioverter-defibrillator (ICD) does not disqualify you — it is simply part of the medical picture underwriters evaluate. A pacemaker for a benign conduction issue in an otherwise healthy senior has modest impact. An ICD implanted for ischemic cardiomyopathy with a low ejection fraction signals more serious disease and usually supports a shorter life expectancy estimate, which tends to increase offers. What matters is the underlying condition the device treats, documented in your cardiology records, not the device itself.

Should I use my policy’s accelerated death benefit instead of selling after a cardiac diagnosis?

Check the rider first — always. If your policy includes an accelerated death benefit and your cardiac condition meets its trigger (terminal illness with limited life expectancy, or chronic illness under some riders), acceleration pays you directly from the carrier, preserves part of the death benefit, and is often income-tax-free under IRC 101(g). A settlement may still make more sense if your condition does not meet the rider’s definitions, if the rider caps the advance below what you need, or if ongoing premiums are unaffordable. Comparing both, with the rider terms in hand, is the correct sequence.

What medical records do I need for a life settlement with heart disease?

Plan on roughly five years of records. The most influential documents for cardiac cases are your most recent echocardiogram (for ejection fraction), cardiology consultation notes, stress test or catheterization reports, hospital discharge summaries, current medication list, and relevant labs such as BNP. Complete, current records help the two independent life expectancy underwriters assess your actual condition; missing records tend to produce more conservative — meaning longer — life expectancy estimates, which lowers offers. Your broker or the provider typically handles record collection with your HIPAA authorization.

Is a life settlement taxable if I sell because of heart disease?

Usually yes, in part. Under IRS Rev. Rul. 2009-13 as modified by the 2017 Tax Cuts and Jobs Act, proceeds up to your premium basis are tax-free, the portion between basis and cash surrender value is ordinary income, and anything above that is capital gain. The major exception is a viatical settlement: if a physician certifies life expectancy under 24 months, proceeds are generally excluded from income under IRC 101(g). Serious heart disease alone does not qualify unless it reaches that terminal threshold, so confirm your classification with a tax professional before selling.

Will selling my policy affect my Medicaid eligibility if my heart condition worsens?

It can. Life settlement proceeds are countable assets for Medicaid purposes, so a lump sum may push you over asset limits and delay eligibility for Medicaid long-term care coverage until the funds are spent down on allowable expenses. If advancing heart failure could eventually require nursing home care funded by Medicaid, consult an elder law attorney before closing. Some states permit structuring proceeds toward long-term care expenses, and the timing of a sale relative to a Medicaid application matters. Planning ahead prevents an avoidable coverage gap.

Can I sell a term life policy if I have heart disease?

Only in limited circumstances. Buyers generally purchase permanent policies — universal life, whole life, variable and indexed UL, and survivorship policies. A term policy is usually only marketable if it is still within its conversion window, allowing the buyer to convert it to permanent coverage after purchase. If you hold convertible term and have a significant cardiac diagnosis, act before the conversion deadline; an expired conversion privilege typically makes the policy unsellable regardless of health status. Check your policy schedule or ask your carrier for the conversion cutoff date.

Related Reading

• How Health Affects Life Settlement Value
• Life Expectancy Settlement Pricing
• Life Settlement Serious Health Condition
• What Is A Life Settlement

---

Pine Lake Life Solutions does not purchase life insurance policies and does not provide legal, tax, or investment advice. Information provided is for educational purposes only. Eligibility for any option, including life settlements, is not guaranteed and depends on individual circumstances, policy terms, underwriting, and market conditions. Consult independent legal, tax, or financial professionals before making decisions regarding a life insurance policy.